Clinical Trials on mCRPC in Italy

Total 8 results

Istituto Scientifico Romagnolo per lo Studio e...

Recruiting

Investigation of PSMA PET/CT as an Imaging Biomarker in Solid Tumors (BASKET PSMA)

Prostate-specific Membrane Antigen | mCRPC or Advanced/Metastatic Solid Tumors

Italy
Pfizer
Astellas Pharma Inc

Active, not recruiting

Talazoparib + Enzalutamide vs. Enzalutamide Monotherapy in mCRPC (TALAPRO-2)

mCRPC

China, Finland, Spain, United States, Hungary, Israel, Belgium, Korea, Republic of, France, Canada, Czechia, Australia, Japan, Brazil, Germany, Argentina, New Zealand, United Kingdom, Norway, South Africa, Poland, Portugal, Chile, Italy, Pe... and more
Istituto Scientifico Romagnolo per lo Studio e...

Terminated

The Role of WB-MRI in the Evaluation of Prostate Cancer Patients Treated With Lutetium - Prostate Specific Membrane Antigen (Lu-PSMA) (WB-LuPSMA)

Metastatic Castration Resistant Prostate Cancer (mCRPC)

Italy
Bristol-Myers Squibb

Completed

Phase I/II Combination With Irinotecan- Erbitux

Metastatic Colorectal Cancer (MCRC)

United States, Italy, Korea, Republic of, Spain, Sweden, Argentina, Denmark
Merck Sharp & Dohme LLC
Orion Corporation, Orion Pharma

Recruiting

A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)

Prostatic Neoplasms | Metastatic Castration-resistant Prostate Cancer (mCRPC)

Australia, Germany, United States, Puerto Rico, Israel, Korea, Republic of, Taiwan, China, Costa Rica, Guatemala, Spain, France, Hong Kong, Portugal, Romania, Chile, Czechia, Hungary, Italy, Sweden, Turkey, United Kingdom, Estonia, Ir... and more
Bayer

Recruiting

Investigation of Radium-223 Dichloride (Xofigo), a Treatment That Gives Off Radiation That Helps Kill Cancer Cells, Compared to a Treatment That Inactivates Hormones (New Antihormonal Therapy, NAH) in Patients With Prostate Cancer That Has Spread to the Bone Getting Worse on or After Earlier NAH

Metastatic Castrate Resistant Prostate Cancer (mCRPC)

Czechia, France, Hungary, Italy, Poland, Spain, Taiwan, United Kingdom, Korea, Republic of, Singapore, Hong Kong, Australia, Finland, Germany, Israel, Lithuania, Russian Federation, Turkey, Austria
Astellas Pharma Global Development, Inc.
Medivation LLC, a wholly owned subsidiary of Pfizer Inc.

Completed

A Study to Evaluate the Potential Increased Risk of Seizures Among Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients Treated With Enzalutamide (UPWARD)

Metastatic Castration-resistant Prostate Cancer (mCRPC)

France, Germany, Spain, United States, Argentina, Australia, Belgium, Canada, Chile, Czechia, Finland, Hungary, Israel, Italy, Korea, Republic of, New Zealand, Singapore, Sweden, Taiwan, United Kingdom
Novartis Pharmaceuticals

Terminated

A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin Lymphoma

Melanoma | Head and Neck Cancer | Pancreatic Cancer | Urothelial Cancer | NSCLC, Non Small Cell Lung Cancer | RCC, Renal Cell Cancer | DLBCL, Diffused Large B Cell Lymphoma | MSS, Microsatellite Stable Colon Cancer | TNBC, Triple Negative Breast Cancer | mCRPC, Metastatic Castration Resistant Prostate...

Belgium, Italy, Taiwan, Germany, Spain, United States, Argentina, Australia, Austria, Czechia, France, Japan, Netherlands, Switzerland, Singapore

Clinical Trials on mCRPC in Italy

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Latvia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations